🚀 VC round data is live in beta, check it out!
Shanghai Hile Bio-Tech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Shanghai Hile Bio-Tech and similar public comparables like Opus Genetics, Elite Pharmaceuticals, Recbio, Racura Oncology and more.
Shanghai Hile Bio-Tech Overview
About Shanghai Hile Bio-Tech
Shanghai Hile Bio-Technology Co Ltd is a veterinary biological product manufacturer integrating research and development, production, sales, and service. The company has over 40 categories of poultry, livestock, and pets. The company provides services for the prevention of livestock diseases, improving the health of livestock and poultry, and improving the production efficiency of farmers, and is able to provide comprehensive solutions and an authoritative veterinary expert service system.
Founded
1981
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$346M
Shanghai Hile Bio-Tech Financials
Shanghai Hile Bio-Tech reported last fiscal year revenue of $40M and EBITDA of $37M.
In the same fiscal year, Shanghai Hile Bio-Tech generated $24M in gross profit, $37M in EBITDA, and $25M in net income.
Shanghai Hile Bio-Tech P&L
In the most recent fiscal year, Shanghai Hile Bio-Tech reported revenue of $40M and EBITDA of $37M.
Shanghai Hile Bio-Tech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $40M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $24M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 60% | XXX | XXX | XXX |
| EBITDA | — | XXX | $37M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 93% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 11% | XXX | XXX | XXX |
| Net Profit | — | XXX | $25M | XXX | XXX | XXX |
| Net Margin | — | XXX | 63% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Shanghai Hile Bio-Tech Stock Performance
Shanghai Hile Bio-Tech has current market cap of $412M, and enterprise value of $346M.
Market Cap Evolution
Shanghai Hile Bio-Tech's stock price is $0.63.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $346M | $412M | -5.1% | XXX | XXX | XXX | $0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialShanghai Hile Bio-Tech Valuation Multiples
Shanghai Hile Bio-Tech trades at 8.7x EV/Revenue multiple, and 9.4x EV/EBITDA.
Shanghai Hile Bio-Tech Financial Valuation Multiples
As of April 19, 2026, Shanghai Hile Bio-Tech has market cap of $412M and EV of $346M.
Equity research analysts estimate Shanghai Hile Bio-Tech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Shanghai Hile Bio-Tech has a P/E ratio of 16.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $412M | XXX | $412M | XXX | XXX | XXX |
| EV (current) | $346M | XXX | $346M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 8.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 9.4x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 79.9x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 14.4x | XXX | XXX | XXX |
| P/E | — | XXX | 16.4x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 61.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Shanghai Hile Bio-Tech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Shanghai Hile Bio-Tech Margins & Growth Rates
Shanghai Hile Bio-Tech's revenue in the last fiscal year grew by 13%.
Shanghai Hile Bio-Tech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 93% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 148% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 12% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 13% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 49% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Shanghai Hile Bio-Tech Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Shanghai Hile Bio-Tech | XXX | XXX | XXX | XXX | XXX | XXX |
| Opus Genetics | XXX | XXX | XXX | XXX | XXX | XXX |
| Elite Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Recbio | XXX | XXX | XXX | XXX | XXX | XXX |
| Racura Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Enanta Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Shanghai Hile Bio-Tech M&A Activity
Shanghai Hile Bio-Tech acquired XXX companies to date.
Last acquisition by Shanghai Hile Bio-Tech was on XXXXXXXX, XXXXX. Shanghai Hile Bio-Tech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Shanghai Hile Bio-Tech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialShanghai Hile Bio-Tech Investment Activity
Shanghai Hile Bio-Tech invested in XXX companies to date.
Shanghai Hile Bio-Tech made its latest investment on XXXXXXXX, XXXXX. Shanghai Hile Bio-Tech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Shanghai Hile Bio-Tech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Shanghai Hile Bio-Tech
| When was Shanghai Hile Bio-Tech founded? | Shanghai Hile Bio-Tech was founded in 1981. |
| Where is Shanghai Hile Bio-Tech headquartered? | Shanghai Hile Bio-Tech is headquartered in China. |
| Is Shanghai Hile Bio-Tech publicly listed? | Yes, Shanghai Hile Bio-Tech is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Shanghai Hile Bio-Tech? | Shanghai Hile Bio-Tech trades under 603718 ticker. |
| When did Shanghai Hile Bio-Tech go public? | Shanghai Hile Bio-Tech went public in 2015. |
| Who are competitors of Shanghai Hile Bio-Tech? | Shanghai Hile Bio-Tech main competitors are Opus Genetics, Elite Pharmaceuticals, Recbio, Racura Oncology. |
| What is the current market cap of Shanghai Hile Bio-Tech? | Shanghai Hile Bio-Tech's current market cap is $412M. |
| What is the current revenue of Shanghai Hile Bio-Tech? | Shanghai Hile Bio-Tech's last fiscal year revenue is $40M. |
| What is the current EV/Revenue multiple of Shanghai Hile Bio-Tech? | Current revenue multiple of Shanghai Hile Bio-Tech is 8.7x. |
| Is Shanghai Hile Bio-Tech profitable? | No, Shanghai Hile Bio-Tech is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.